We are live on !
Find out more
SGAM
Smith Group Asset Management Portfolio holdings
AUM
$2.46B
Turnover
25.53%
1-Year Est. Return
57.16%
This Fund
S&P 500
This Quarter Est. Return
+7.77%
1 Year Est. Return
+57.16%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.38B
AUM Growth
+$750M
(+28%)
Cap. Flow
+$1.01B
Cap. Flow % of AUM
Cap. Flow %
29.86%
Top 10 Holdings %
Top 10 Hldgs %
27.81%
Holding
544
New
135
Increased
136
Reduced
128
Closed
73
Avg Time Held
1.1
years
Top 10 Avg Time Held
1
year
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$389M |
| 2 |
Microsoft
MSFT
|
+$95.1M |
| 3 |
Apple
AAPL
|
+$51.5M |
| 4 |
Masco
MAS
|
+$45.7M |
| 5 |
McDonald's
MCD
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
F5
FFIV
|
+$49M |
| 2 |
MSCI
MSCI
|
+$30.2M |
| 3 |
Pilgrim's Pride
PPC
|
+$29.4M |
| 4 |
Amdocs
DOX
|
+$22.9M |
| 5 |
Ansys
ANSS
|
+$21.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.94% |
| 2 | Consumer Discretionary | 19.08% |
| 3 | Healthcare | 18.98% |
| 4 | Industrials | 12.08% |
| 5 | Consumer Staples | 10.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
CHMT
176
DELISTED
Chemtura Corporation
CHMT
| $895K | 0.03% |
+32,830
| New | +$977K |
2015 Q4
0 quarters
|
|
177
Inovio Pharmaceuticals
INO
$102M
| $870K | 0.03% |
10,785
-1,709
| -14% | -$136K |
2014 Q2
6 quarters
|
|
178
Ultragenyx Pharmaceutical
RARE
$1.43B
| $856K | 0.03% |
+7,630
| New | +$763K |
2015 Q4
0 quarters
|
|
|
ANAC
179
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $851K | 0.03% |
7,530
+3,420
| +83% | +$377K |
2015 Q3
1 quarter
|
|
180
DELISTED
ARM HOLDINGS PLC ADS
ARMH
| $845K | 0.03% |
+18,683
| New | +$882K |
2015 Q4
0 quarters
|
|
181
Ziff Davis
ZD
$1.96B
| $826K | 0.02% |
+11,546
| New | +$784K |
2015 Q4
0 quarters
|
|
|
SCAI
182
DELISTED
Surgical Care Affiliates, Inc.
SCAI
| $803K | 0.02% |
20,180
-3,500
| -15% | -$122K |
2014 Q4
4 quarters
|
|
183
BioCryst Pharmaceuticals
BCRX
$1.99B
| $789K | 0.02% |
+76,410
| New | +$760K |
2015 Q4
0 quarters
|
|
184
Halozyme
HALO
$13.8B
| $752K | 0.02% |
43,380
-6,700
| -13% | -$107K |
2015 Q3
1 quarter
|
|
185
Cohen & Steers
CNS
$3.58B
| $725K | 0.02% |
+23,800
| New | +$715K |
2015 Q4
0 quarters
|
|
186
DELISTED
Berry Global Group, Inc.
BERY
| $690K | 0.02% |
+20,778
| New | +$659K |
2015 Q4
0 quarters
|
|
|
CERN
187
DELISTED
Cerner Corp
CERN
| $688K | 0.02% |
+11,429
| New | +$703K |
2015 Q4
0 quarters
|
|
|
NAVG
188
DELISTED
Navigators Group Inc
NAVG
| $686K | 0.02% |
15,986
-2,400
| -13% | -$102K |
2013 Q2
10 quarters
|
|
189
V2X
VVX
$2.2B
| $678K | 0.02% |
+32,440
| New | +$756K |
2015 Q4
0 quarters
|
|
190
Myriad Genetics
MYGN
$381M
| $650K | 0.02% |
+15,060
| New | +$636K |
2015 Q4
0 quarters
|
|
191
WSFS Financial
WSFS
$3.9B
| $628K | 0.02% |
19,400
+15,560
| +405% | +$497K |
2013 Q2
10 quarters
|
|
192
DELISTED
Heidrick & Struggles
HSII
| $618K | 0.02% |
+22,690
| New | +$594K |
2015 Q4
0 quarters
|
|
|
DTSI
193
DELISTED
DTS, Inc.
DTSI
| $615K | 0.02% |
27,250
-2,340
| -8% | -$62.2K |
2014 Q2
6 quarters
|
|
194
Merck
MRK
$360B
| $613K | 0.02% |
12,164
+12,136
| +43,343% | +$612K |
2014 Q4
4 quarters
|
|
|
CPHD
195
DELISTED
Cepheid Inc
CPHD
| $609K | 0.02% |
+16,670
| New | +$592K |
2015 Q4
0 quarters
|
|
196
Acadia Pharmaceuticals
ACAD
$3.29B
| $601K | 0.02% |
+16,870
| New | +$594K |
2015 Q4
0 quarters
|
|
|
ALJ
197
DELISTED
Alon USA Energy Inc
ALJ
| $572K | 0.02% |
38,560
-5,900
| -13% | -$98.7K |
2014 Q4
4 quarters
|
|
198
Regional Management Corp
RM
$317M
| $545K | 0.02% |
35,210
+30,520
| +651% | +$480K |
2015 Q1
3 quarters
|
|
199
American Express
AXP
$212B
| $525K | 0.02% |
+7,551
| New | +$549K |
2015 Q4
0 quarters
|
|
|
PTLA
200
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $511K | 0.02% |
+9,940
| New | +$482K |
2015 Q4
0 quarters
|
|
Similar funds
MAMU
PC
RG
DIA
Smith Group Asset Management's Q4 2015 Portfolio in Review
As of Q4 2015, Smith Group Asset Management held 544 positions worth $3.38B, up 28% from $2.63B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Smith Group Asset Management deployed $1.01B of net new capital in Q4 2015, opening 135 new positions and adding to 136 existing holdings. Its largest new stake was Masco: 1,605,910 shares worth $45.4M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Lockheed Martin, an estimated $15.9M trimmed.
- Smith Group Asset Management's largest Q4 2015 buy was Masco: 1,605,910 shares worth $45.4M.
- Smith Group Asset Management added most to Allergan plc in Q4 2015, an estimated $389M increase.
- Smith Group Asset Management's biggest Q4 2015 reduction was Lockheed Martin, cutting an estimated $15.9M.
- Smith Group Asset Management fully exited F5 in Q4 2015, selling an estimated $49M.
- Smith Group Asset Management's ten largest holdings make up 28% of its $3.38B portfolio in Q4 2015.
- Smith Group Asset Management opened 135 new positions and closed 73 in Q4 2015.
- Smith Group Asset Management's portfolio value rose 28% quarter-over-quarter to $3.38B.
Based on Smith Group Asset Management's 13F filing for Q4 2015, filed 3 Feb 2016.